Clinical trials: Metastatic Colorectal Carcinoma
Colorectal Cancer
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00107315
- Testing
- bevacizumab, capecitabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer
Phase II Fixed Dose Rate Gemcitabine for Advanced or Metastatic Colorectal Cancer
To assess the efficacy and safety of gemcitabine given by fixed dose rate intravenous infusion in patients with pretreated metastatic colorectal cancer.
- Trial name
- NCT00220155
- Testing
- Gemcitabine
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Colorectal Neoplasms, Intestinal Neoplasms
Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
Bevacizumab, as an antibody of vascular endothelial generated factor (VEGF), combined with the fluorouracil-based chemotherapy regimens for metastatic colorectal cancer, has become the classical first-line treatment.
- Conditions
- Colorectal Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms
- Trial name
- NCT03271255
- Testing
- Apatinib Mesylate Tablets, Bevacizumab Injection
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shenzhen People's Hospital
Pancreatic Neoplasms, Hepatocellular Cancer
Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm
The purpose of the study is to evaluate whether the novel anti-cancer drug OXY111A is safe and tolerated in patients with primary and secondary hepato-pancreato-biliary and gastrointestinal neoplasia as measured by exploring the…
- Conditions
- Pancreatic Neoplasms, Hepatocellular Cancer, Cholangiocarcinoma, Colorectal Neoplasms
- Trial name
- OXY1A (NCT02528526)
- Testing
- OXY111A
- Where
- Switzerland
- Volunteers
- 69 people
- Sponsor
- University of Zurich
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors.
- Trial name
- NCT07488676
- Testing
- ASP546C
- Where
- 21 sites in United States, Japan
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Colorectal Cancer
Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cyclosporine may relieve the diarrhea caused by irinotecan.
- Trial name
- NCT00003950
- Testing
- cyclosporine, CPT-11
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Colorectal Cancer
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Patients with metastatic colorectal cancer will be treated with chemotherapy according to investigators choice. In addition to chemotherapy treatment, treatment with bevacizumab will be given concomitantly.
- Trial name
- ACT2 (NCT01229813)
- Testing
- bevacizumab, erlotinib, bevacizumab, low dose capecitabine
- Where
- 12 sites in Denmark, Sweden
- Volunteers
- 233 people
- Sponsor
- Lund University Hospital
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
- Trial name
- NCT06607185
- Testing
- LY4066434., Cetuximab, Nab paclitaxel
- Where
- 45 sites in United States, Belgium and 6 more
- Volunteers
- 750 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
Immunophenotyping of Metastases From Colorectal Cancer
Immune therapy represents a promising option for the treatment of an increasing number of malignancies. New immunotherapeutic strategies are currently under development and will be further studied starting from refractory…
- Trial name
- NCT03604926
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Colorectal Cancer
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00280176
- Testing
- bortezomib, fluorouracil, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Adenocarcinoma
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
The purpose of this study is to collect information about the antitumor activity and the safety of capecitabine and thalidomide in patients with colorectal cancer.
- Trial name
- NCT00165217
- Testing
- Capecitabine, Thalidomide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dana-Farber Cancer Institute
Solid Tumors
A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety, tolerability and preliminary efficacy of KIVU-305, a CEACAM5-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid…
- Trial name
- NCT07545356
- Testing
- KIVU-305
- Where
- 3 sites in Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.
Recurrent Colon Cancer, Recurrent Rectal Cancer
Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
This phase II trial is studying dasatinib to see how well it works in treating patients with previously treated metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT00504153
- Testing
- dasatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer
This study is being done to select an appropriate TF2 bsMAb dose suitable for pretargeting the 111In/90Y-labeled hapten-peptide (IMP-288).
- Trial name
- NCT01273402
- Testing
- TF2/IMP288
- Where
- United States
- Sponsor
- Gilead Sciences
Unresectable/Metastatic Colorectal Cancer
Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer
FOLFOXIRI-based regimen is more used as a first-line therapeutic approach for patients diagnosed with unresectable or metastatic colorectal cancer for its superior efficacy.
- Trial name
- NCT06148402
- Testing
- Fruquintinib plus camrelizumab and capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
BRAF V600 Colorectal Cancer
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
The goal of this clinical trial is to learn if Iparomlimab and Tuvonralimab combined with bevacizumab and FOLFIRI (IB-FOLFIRI) is safe and effective in treating adults with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
- Trial name
- NCT07150247
- Testing
- Iparomlimab and Tuvonralimab, Bevacizumab, 5-Fluorouracil
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
HIV Infection, Recurrent Anal Cancer
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
This phase I clinical trial is studying the side effects and the best dose of vorinostat when given together with paclitaxel and carboplatin in treating patients with metastatic or recurrent solid tumors and human…
- Conditions
- HIV Infection, Recurrent Anal Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer
- Trial name
- NCT01249443
- Testing
- vorinostat, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 10 sites in United States
- Volunteers
- 17 people
- Sponsor
- AIDS Malignancy Consortium
Metastatic Colorectal Cancer
Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer
To control apatinib and capecitabine combination to maintain treating metastatic colorectal cancer.
- Trial name
- NCT03132025
- Testing
- "Apatinib" and "Capecitabine", "Capecitabine"
- Volunteers
- 40 people
- Sponsor
- Yanqiao Zhang
Colorectal Cancer Metastatic
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
The prognosis of most patients with unresectable locally advanced or metastatic colorectal cancer (CRC) remains poor despite the advancements in chemotherapy and target therapy.
- Trial name
- NCT06685276
- Testing
- Fruquintinib, Sintilimab, Chidamide
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Dai, Guanghai
Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
This phase I trial studies the side effects and the best dose of lenalidomide when given together with cetuximab in treating patients with colorectal cancer or head and neck cancer that has spread to other places in the body and…
- Conditions
- Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
- Trial name
- ADCC (NCT01254617)
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Lenalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.